PharmaCyte Biotech
PMCB
PMCB
30 hedge funds and large institutions have $9.93M invested in PharmaCyte Biotech in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less ownership
Funds ownership: →
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
17% less capital invested
Capital invested by funds: $12M → $9.93M (-$2.03M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
30
Holding in Top 10
1
Calls
$522K
Puts
$566K
Top Buyers
| 1 | +$354K | |
| 2 | +$90K | |
| 3 | +$60.7K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$51.1K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$50.3K |
Top Sellers
| 1 | -$2.44M | |
| 2 | -$1.38M | |
| 3 | -$480K | |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$180K |
| 5 |
Millennium Management
New York
|
-$60K |